By efrat|2023-08-20T08:11:01+00:00August 26th, 2023|All|Comments Off on Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL
By efrat|2023-08-20T08:11:42+00:00August 14th, 2023|All|Comments Off on Aug 21st 2023- Dr. Ashwin Kishtagari- His Take on the Recent Approval of Quizartinib by FDA in AML
By efrat|2023-08-20T08:12:17+00:00August 14th, 2023|All|Comments Off on Aug 16th 2023- Dr. Jayastu Senapati- Prognostic Impact of Splicing Factor Mutations in Patients with Newly Diagnosed AML
By efrat|2023-08-20T08:13:11+00:00August 6th, 2023|All|Comments Off on Aug 8th 2023- Dr. Tania Jain- Haploidentical Donor Hematopoietic Cell Transplantation for MDS/MPN Overlap Neoplasms: Results from a North American Collaboration
By efrat|2023-08-20T08:13:42+00:00July 30th, 2023|All|Comments Off on Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma
By efrat|2023-08-20T08:15:00+00:00July 24th, 2023|All|Comments Off on July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial
By efrat|2023-08-20T08:16:13+00:00July 16th, 2023|All|Comments Off on July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results
By efrat|2023-08-20T08:17:37+00:00July 9th, 2023|All|Comments Off on July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues
By efrat|2023-08-20T08:52:36+00:00May 9th, 2023|All|Comments Off on May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL
By efrat|2023-08-20T08:53:28+00:00May 2nd, 2023|All|Comments Off on May 5th 2023- Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation